We have recently shown that ghrelin, a novel orexigenic hormone, is reduced in sepsis. Ghrelin treatment, mediated through ghrelin receptors in the brain, attenuates sepsis-induced inflammation and mortality. Gut barrier dysfunction is common in sepsis. High-mobility group B1 (HMGB1) increases gut permeability both in vitro and in vivo. However, it remains unknown whether ghrelin has any effects on HMGB1 and gut barrier function in sepsis. We hypothesized that ghrelin decreases HMGB1 release and attenuates sepsis-induced gut barrier dysfunction through central ghrelin receptors.
S epsis remains a critical problem with significant morbidity and mortality rates, even in the modern era of critical care management (1, 2) . Gut barrier dysfunction, manifested by increased mucosal permeability to hydrophilic macromolecules and increased bacterial translocation to mesenteric lymph nodes (MLN), occurs in sepsis (3) (4) (5) . The decrease in gut barrier function has been associated with augmentation of systemic inflammation and distant organ dysfunction under such conditions (5, 6) . Thus, the therapeutic potential for an agent to prevent gut barrier compromise and attenuate gut-derived inflammatory response is significant.
Ghrelin, an orexigenic hormone, was first identified in the rat stomach in 1999 as an endogenous ligand for the growth hormone secretagogue receptor type 1a (GHSR-1a, i.e., ghrelin receptor) (7) . Recent studies have indicated that ghrelin plays an important role in the regulation of pituitary hormone secretion, feeding, energy homeostasis, gastrointestinal function, and cardiovascular and immune system (8 -10) . Our recent studies have shown that circulating levels of ghrelin decreased significantly in a rat model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), and ghrelin administration decreases tumor necrosis factor-␣ and interleukin-6, increases cardiac output, improves organ blood flow, and reduces mortality rate under such conditions (10 -13) . The beneficial effect of ghrelin in sepsis is mediated through ghrelin receptors in the central nervous system (10, 14) .
High-mobility group box 1 (HMGB1) is a late mediator of lethal sepsis (15) . Once outside the cell, it acts as a potent mediator of inflammation (16). HMGB1 levels are significantly elevated in the blood of septic patients (15, 17) , suggesting that extracellular HMGB1 is involved in the pathogenesis of sepsis (18 -20) . A study has shown that HMGB1 increases gut permeability both in vitro and in vivo (21). Blockade of HMGB1 improves gut barrier function and decreases mortality rate after shock (22). However, it remains unknown whether ghrelin has any effects on HMGB1 levels and gut barrier function in polymicrobial sepsis. This study was conducted to test the hypothesis that ghrelin decreases HMGB1 levels and attenuates sepsis-induced gut barrier dysfunction through central ghrelin receptors.
MATERIALS AND METHODS
Experimental Animals. Male Sprague-Dawley rats (275-325 g), purchased from isothiocyanate dextran, bacterial counts in the mesenteric lymph nodes complex, and gut water content were determined. In additional groups of animals, bilateral trunk vagotomy was performed at 5 hrs after CLP before ghrelin injection. Furthermore, to confirm the role of central ghrelin receptors in ghrelin's effect, ghrelin (1 nmol) was administered through intracerebroventricular injection at 5 hrs after CLP. Our results showed that brain levels of ghrelin decreased by 34% at 20 hrs after CLP. Intravenous administration of ghrelin completely restored brain levels of ghrelin, significantly reduced the elevated HMGB1 levels, and attenuated gut barrier dysfunction. Vagotomy eliminated ghrelin's inhibition of HMGB1 and attenuation of gut barrier dysfunction. Intracerebroventricular injection of ghrelin decreased serum HMGB1 levels and ameliorated gut barrier dysfunction.
Conclusions: Ghrelin reduces serum HMGB1 levels and ameliorates gut barrier dysfunction in sepsis by vagus nerve activation via central ghrelin receptors. Ghrelin can be further developed as a novel agent to protect gut barrier function in sepsis. (Crit Care Med 2009; 37:2421-2426) KEY WORDS: sepsis; ghrelin; gut barrier function
Charles River Laboratories (Wilmington, MA), were used in this study. The rats were housed in a temperature-controlled room on a 12-hr light/dark cycle and fed on a standard Purina rat chow diet. The rats were fasted for 12 hrs before the procedure. Animal experimentation was carried out in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources). This project was approved by the Institutional Animal Care and Use Committee of The Feinstein Institute for Medical Research. Animal Model of Sepsis. Sepsis was induced by CLP as previously described (13) . Briefly, the rats were anesthetized and a 2-cm ventral midline abdominal incision was performed. The cecum was then exposed, ligated just distal to the ileocecal valve to avoid intestinal obstruction, punctured twice with an 18gauge needle, and returned to the abdominal cavity. The incision was then closed in layers. Sham-operated animals (i.e., control animals) underwent the same procedure with the exception that the cecum was neither ligated nor punctured. The animals were resuscitated with 3 mL of normal saline per 100 g of body weight given subcutaneously immediately after surgery. The animals were then returned to their cages with free access to food and water.
Intravenous Injection of Ghrelin. Rat ghrelin (Phoenix Pharmaceuticals, Belmont, CA) was dissolved in normal saline to a final concentration of 100 M. Then 200-L minipumps (Alzet, infusion rate 8 L/hr) were primed with ghrelin solution or vehicle (normal saline) for 3 hrs before implantation. After a slow, intravenous bolus injection of 2 nmol ghrelin (or 200 L vehicle) at 5 hrs after CLP (i.e., posttreatment), the mini-pump was connected to a jugular venous catheter and implanted subcutaneously. Twenty hours after CLP (i.e., 15 hrs after implantation of the mini-pump), the rats were killed and blood and tissue samples were collected. The total dose of ghrelin each rat received was 14 nmol (i.e., approximately 45 nmol per 1 kg of body weight). The dose of ghrelin was determined based on our previous experience (10, 12) .
Vagotomy. In additional groups of animals, the trunks of the subdiaphragmatic vagus were transected as previously described (10) . Briefly, the rats were reanesthetized with isoflurane inhalation at 5 hrs after CLP or sham operation. The midline abdominal incision was reopened before the administration of ghrelin, and the dorsal and ventral branches of the vagus nerve were dissected from the esophagus. Ghrelin or vehicle (normal saline) was administrated intravenously immediately following vagotomy as described previously in the vagus-nerve-intact animals. Twenty hours after CLP (i.e., 15 hrs after implantation of the mini-pump), the rats were killed and blood and tissue samples were collected.
Intracerebroventricular (ICV) Injection of Ghrelin. ICV injection of ghrelin was performed as described recently (14) . Briefly, rats were anesthetized with pentobarbital (intra-peritoneal injection, 40 mg per 1 kg of body weight) and placed in a stereotactic head frame (Stoelting, Wood Dale, IL) at 5 hrs after CLP. The incisor bar was adjusted until the plane defined by the lambda and bregma was parallel to the base plate. The musculature on the skull was removed, and the skull was exposed. A hole (1-2 mm in diameter) was drilled through the skull with a hand-operated drill (Dremel Robert Bosch Tool, Mount Prospect, IL). The needle of a Hamilton syringe (25 L) was stereotactically guided into lateral ventricle (0.8 mm posterior to bregma, 1.5 mm lateral to midline, 3.0 mm below the dura). Ghrelin (1 nmol) was dissolved in sterile endotoxin-free normal saline (10 L) and administered in 1 min. The hole was sealed by the use of cyanoacrylic glue. The rats were then removed from the stereotactic head frame and placed in a supine position on an acrylic board. Twenty hours after CLP, the rats were killed and blood and tissue samples were collected. The location of ICV injections was confirmed by histologic examination of the brain after the experiment.
Determination of Brain Ghrelin Levels. At 20 hrs after CLP or sham operation, brain samples were rapidly harvested. The tissues were excised, rinsed of blood, homogenized with polytron in a homogenization buffer (phosphate-buffered saline solution, containing 0.05% Triton X-100 and a protease inhibitor cocktail; pH, 7.2; 4°C), and sonicated for 10 secs. Homogenates were centrifuged at 12,000g for 10 mins, and ghrelin levels were quantified using an enzyme-linked immunosorbent assay kit specifically for human and rat active ghrelin (100% cross-reactivity with rat active ghrelin; Linco Research, St. Charles, MO). The assay was carried out according to the instructions provided by the manufacturer. Brain levels of ghrelin were normalized to the protein concentration in the sample.
Determination of HMGB1. The levels of HMGB1 in the serum were assayed by Western blot analysis using rabbit polyclonal antibodies. Briefly, serum (5 L) was fractionated on 4% to 12% Bis-Tris gel and transferred to a 0.2-m nitrocellulose membrane. Nitrocellulose blots were blocked by incubation in TBST (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20) containing 5% milk for 1 hr. Blots were incubated with rabbit anti-rat antibodies overnight at 4°C. The blots were then washed in TBST for 5 ϫ 10 mins. Blots were incubated with horseradish peroxidase-labeled goat antirabbit immunoglobulin G for 1 hr at room temperature. The blots were then washed in TBST for 5 ϫ 10 mins. A chemiluminescent peroxidase substrate (ECL, Amersham Biosciences) was applied according to the manufacturer's instruction, and the membranes were exposed to radiographic film. The Western blot relative band intensity was quantified by ChemiImager 5500 software. The levels of HMGB-1 were calculated with reference to standard curves generated from purified rHMGB-1.
Determination of Intestinal Mucosal Permeability.
Intestinal barrier function was assessed by measuring translocation of the fluorescent tracer, fluorescein isothiocyanate dextran with a molecular weight of 4000 Da (FD4, Sigma) by the everted gut sac method as described by Fink and associates (3, (22) (23) (24) and recently used by us (25). Briefly, an approximately 15-cm-long ileal segment was harvested from each animal at 20 hrs after CLP or sham operation. Gut sacs were prepared in ice-cold modified Krebs-Henseleit bicarbonate buffer (pH 7.4). One end of the gut segment was ligated with suture, and then the segment was everted onto a thin plastic rod. The resulting sac was secured with another suture to the grooved tip of a 3-mL plastic syringe containing Krebs-Henseleit bicarbonate buffer. The sac was gently distended by injecting 1.5 mL of Krebs-Henseleit bicarbonate buffer and suspended for 30 mins in a 50-mL beaker containing 40 mL of Krebs-Henseleit bicarbonate buffer plus FD4 (40 mg/ mL). The solution in the beaker was temperature jacketed at 37°C and was continuously bubbled with a gas mixture containing 95% oxygen and 5% CO 2 . The FD4 concentration of the fluid in the beaker and the inside of the sac was determined spectrofluorometrically, and permeability was expressed as the mucosal-toserosal clearance of FD4.
Determination of Bacterial Translocation. The MLN complex was harvested and rinsed carefully in a large volume of sterile normal saline to minimize the possibility of bacteria contamination from the peritoneal cavity. Equal amounts of wet tissues were homogenized and briefly centrifuged to remove gross particulate matters. Serial log dilutions of tissue homogenates were applied. Then 500 L of each dilution was plated on chocolate agar plates (Fisher Scientific, Pittsburgh, PA) and incubated at 37°C for 24 hrs under aerobic conditions. The colony-forming units were counted, and results were expressed as colonyforming units per gram of tissue.
Water Content Determination. Gut edema was estimated by comparing tissue water content. Briefly, an approximately 5-cm-long ileal segment was harvested from each animal at 20 hrs after CLP or sham operation. Gut tissues were dried in a 70°C oven for 48 hrs. Gut water content was calculated as % H 2 
Statistical Analysis. All data are expressed as mean Ϯ SE and compared by one-way analysis of variance and Student-Newman-Keuls test for multiple group analysis. Differences in values were considered significant if p Ͻ .05.
RESULTS
Brain Levels of Ghrelin Are Reduced in Sepsis. Our previous study showed that circulating ghrelin levels decreased significantly after CLP (11) . However, the alteration in brain ghrelin levels remains unknown. Thus, we measured brain levels of ghrelin after CLP with or without intravenous ghrelin administration. As shown in Figure 1 , brain levels of ghrelin decreased by 34% at 20 hrs after CLP. Intravenous administration of ghrelin restored the reduced brain levels of ghrelin completely. This result also confirms that ghrelin can cross the blood-brain barrier to produce its beneficial effects centrally.
Ghrelin Reduces Serum HMGB1 Levels and Ameliorates Gut Barrier Dysfunction in Sepsis. HMGB1 is a critical mediator of lethal sepsis (15). To examine the effect of ghrelin on HMGB1 release, HMGB1 levels were measured at 20 hrs after CLP with or without ghrelin treatment. As indicated in Figure 2 , serum levels of HMGB1 increased by 1.5-fold at 20 hrs after CLP compared with shamoperated controls (p Ͻ .05). Treatment with ghrelin reduced serum HMGB1 levels by 32% in septic animals (p Ͻ .05, Fig. 2 ). As indicated in Figure 3A , ileal mucosal permeability to the fluorescent macromolecule, FD4, was significantly increased at 20 hrs after CLP in vehicletreated animals compared with sham controls (p Ͻ .05). Similarly, bacterial translocation to MLN was minimal in the sham group but was extensive in the CLP vehicle-treated group (p Ͻ .05, Fig. 3B ). Treatment with ghrelin, however, significantly ameliorated the development of both ileal mucosal hyperpermeability and bacterial translocation. As shown in Figure 3C , rats subjected to sepsis had a significant increase in gut water content (i.e., edema) compared with shamoperated animals (p Ͻ .05). When septic animals were treated with ghrelin, the water content of the gut (p Ͻ .05, Fig.  3C ) was reduced significantly and there was no statistical difference in gut water content between sham-operated and CLP ghrelin-treated animals.
Ghrelin's Beneficial Effects in Sepsis Require the Intact Vagus Nerve. To determine whether ghrelin's beneficial effects in sepsis require the intact vagus nerve, vagotomy was performed in sham and septic animals immediately before the administration of ghrelin. As indi-cated in Figure 4 , vagotomy completely eliminated the beneficial effect of this agent on serum levels of HMGB1. Similarly, ghrelin's effects on ileal mucosal hyperpermeability ( Fig. 5A ), bacterial translocation ( Fig. 5B ) and gut water content (Fig. 5C ) in sepsis were completely abolished by vagotomy. Thus, ghrelin's beneficial effects in sepsis require the intact vagus nerve. We also found that vagotomized rats had much higher serum HMGB1 levels ( Fig. 4 ) than rats with intact vagus nerve (Fig. 2 ). This confirms early observations that vagotomy not only prevents the protective effect of the vagus nerve stimulation but also sensitizes the animal to the lethal effect of endotoxin (26, 27).
ICV Administration of Ghrelin Is Protective in Sepsis. To further confirm that ghrelin's beneficial effects in sepsis are mediated through the central nervous system, ICV administration of ghrelin was performed at 5 hrs after CLP. As shown in Figure 6 , ICV injection of ghrelin significantly inhibited HMGB1 release (p Ͻ .05). Similarly, ICV injection of ghrelin ameliorated ileal mucosal hyperpermeability (p Ͻ .05, Fig. 7A ) and reduced bacterial translocation (p Ͻ .05, Fig. 7B ).
DISCUSSION
Under normal conditions, the intestinal barrier acts as a selective route of entry, allowing movement of necessary molecules through the epithelium but at the same time preventing the entry of potentially pathogenic organisms or their products. Gut barrier dysfunction has been identified in a number of local or systemic inflammatory disorders, including inflammatory bowel disease (28), thermal injury (5), multisystem trauma (22), endotoxemia (29), and sepsis (30). In this study, we found that although histologic sections of the small intestine showed little evidence of massive injury at 20 hrs after CLP (data not shown), gut barrier dysfunction, manifested by increased mucosal permeability to hydrophilic macromolecules (e.g., FD4) and increased bacterial translocation to MLN, presented in these animals. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill patients (4) . It is suspected to be involved in the augmentation of systemic inflammation and distant organ dysfunction under such conditions (5, 6) . The principal findings of the current study are as follows: a) ghrelin ameliorates sepsis-induced gut barrier dysfunction, which is paralleled by reduced serum levels of HMGB1; and b) the beneficial effect of ghrelin in sepsis requires the intact vagus nerve involving the central nervous system.
Ghrelin, a novel gastrointestinal hormone, was originally reported to induce growth hormone release through pituitary GHSR-1a stimulation (7) . However, a large body of evidence has indicated other physiologic functions of ghrelin mediated by the central and peripheral ghrelin receptors (31) . GHSR-1a is found in the brain stem, pituitary, hypothalamus, heart, blood vessels, lungs, stomach, pancreas, intestines, kidneys, and adipose tissue (32) (33) (34) . The wide distribution of GHSR-1a suggests multiple paracrine, autocrine, and endocrine roles of ghrelin (32) (33) (34) (35) . Besides the established effects on food intake and growth hormone production, ghrelin has been shown to mediate a number of functions on a variety of other organ systems, including promotion of adipogenesis, cardiomyocyte survival, enhancement of memory, neurogenesis, and improvement of thymic function (8, 9, 36) . Recently, ghrelin has emerged as a potent immunoregulatory and anti-inflammatory agent (36, 37) . In this study, we showed for the first time that ghrelin ameliorates gut barrier dysfunction in a clinically relevant model of sepsis.
Rodents challenged with lipopolysaccharide develop manifestations of impaired intestinal barrier function, including increased mucosal permeability to hydrophilic macromolecules and increased translocation of viable bacteria to MLNs (38, 39) . However, intestinal barrier dysfunction often is not apparent until many hours after the injection of lipopolysaccharide (40) , suggesting that a late-acting mediator may be pathophysiologically responsible for this phenomenon (21). HMGB1, a 30-kDa nuclear and cytosolic ubiquitous protein, is a DNAbinding protein known as a transcription and growth factor (41, 42) . Structurally, HMGB1 is organized into two DNAbinding domains (named A-box and Bbox) and a negatively charged C-terminus. Recently, extracellular HMGB1 was identified as a late-acting cytokine-like mediator of lipopolysaccharide-induced (15) or sepsis-induced (19) lethality in mice. HMGB1 is actively secreted by immunostimulated macrophages (15, 43) and enterocytes (44) . It is also passively released by injured and necrotic cells and has been shown to trigger necrosisinduced inflammation (45) . The proinflammatory actions of HMGB1 have been localized to the B-box region of the molecule (46) . High concentrations of HMGB1 can be detected in the serum of mice under endotoxemia, and delayed passive immunization of mice with antibodies against HMGB1 confers significant protection against lipopolysaccharideinduced mortality (15). Administration of highly purified recombinant HMGB1 to mice is lethal (15). Recently, Sappington et al (21) showed that recombinant human HMGB1 increased the permeability of Caco-2 human enterocytic monolayers to FD4 in a time-and dose-dependent fashion. The increase in permeability was reversible following removal of the re- combinant protein. Administration of Bbox HMGB1 to wild-type mice increased both ileal mucosal permeability to FD4 and bacterial translocation to MLNs (21). On the other hand, treatment with a neutralizing anti-HMGB1 antibody ameliorated gut barrier dysfunction in a mouse model of hemorrhagic shock (22). In this regard, inhibition of HMGB1 release may contribute to ghrelin's attenuation of gut barrier dysfunction in sepsis. However, a cause-and-effect relationship cannot be established in the current study.
Stimulation of the vagus nerve can rapidly attenuate systemic inflammatory responses by inhibiting the activation of macrophages and endothelial cells. This physiologic mechanism, termed the cholinergic anti-inflammatory pathway, can reflexively monitor and adjust the inflammatory response to prevent excessive inflammation. Tracey and associates (47) (48) (49) found that vagus nerve stimulation, via the activation of nicotinic acetylcholine receptors (␣ 7 receptors), inhibits HMGB1 release and improves survival in animal models of polymicrobial sepsis and endotoxemia. Vagotomy, on the other hand, not only prevents the protective effect of the vagus nerve stimulation but also sensitizes the animals to the lethal effects of endotoxin (26, 49) . It has been reported that ghrelin activates the vagus nerve, and vagal blockade abolishes ghrelin-induced feeding and growth hormone secretion (50) . To determine whether ghrelin's beneficial effects in sepsis involve vagus nerve stimulation, vagotomy was performed in sham and septic animals immediately before the administration of ghrelin. As anticipated, the protection of ghrelin on gut barrier function after CLP requires the intact vagus nerve, because vagotomy prevents its beneficial effects. Ghrelin can cross the blood-brain barrier (51) (52) (53) , and ghrelin receptors are expressed at a high density in the brain (34, 54) . Our current study also showed that brain levels of ghrelin decreased significantly at 20 hrs after CLP, and intravenous administration of ghrelin restored brain levels of ghrelin completely. Furthermore, ICV injection of ghrelin inhibited HMGB1 release and attenuated gut damage after CLP. Therefore, it appears that the stimulatory effect of ghrelin on the vagus nerve is mainly mediated via the central nervous system.
The method we used to determine bacterial translocation is a way to measure the number of bacteria translocated from the intestinal lumen to the MLB.
Because no exogenous bacteria were provided, our method is not intended to determine the percentage of translocation. Other factors such as host immunity can influence bacterial growth and survival of peritoneal bacteria as well as translocating bacteria. Our recent study showed that peritoneal bacterial levels in ghrelintreated animals are lower than those in vehicle-treated animals at 20 hrs after CLP (13) . This is not surprising, because ghrelin can improve host immunity and kill bacteria (55) . Therefore, the bacterial translocation data can only be used as supporting evidence to reflect the degree of loss of gut barrier function. Our results showed that the bacteria translocation data are consistent with the gut permeability data and, therefore, indirectly support our conclusion.
Our previous study showed that sham vagotomy (i.e., the animals underwent the same surgical procedure as vagotomized animals with the exception that their vagus nerves were neither tied nor severed) had no impact on ghrelin's effects on inflammation and organ injury after CLP (10) . Furthermore, as indicated in this article, the percentage-wise increases in gut permeability, bacterial count in the MLN, and gut water content after CLP are similar between vagusnerve-intact and vagotomized animals. Therefore, control groups of sham vagotomy were not included in this study.
Increased expression and activity of inducible nitric oxide synthase have been shown to play a role in sepsis-induced gut barrier dysfunction (56 -58) . Recent studies have shown that both central and peripheral administration of ghrelin can reduce inducible nitric oxide synthase expression in the mucosa and protect against gastrointestinal injury induced by either ethanol or ischemia-reperfusion (59, 60) . Therefore, attenuation of inducible nitric oxide synthase expression by this peptide may also contribute to ghrelin's intestinal protection.
The dose of ghrelin used for ICV injection was only about 7% of the dose for intravenous injection (i.e., 1 nmol vs. 14 nmol). Therefore, the impact of possible ghrelin leakage from the central nervous system to the general circulation after ICV injection is most likely negligible. Furthermore, the location of ICV injections was confirmed by histologic examination of the brain after the experiment.
In this study, either intravenous or ICV injection of ghrelin significantly reduced the elevated HMGB1 levels and at-tenuated gut barrier dysfunction at 20 hrs after CLP. The protection of ghrelin in sepsis requires the intact vagus nerve, because vagotomy eliminated ghrelin's inhibition of HMGB1 and attenuation of gut barrier dysfunction. Thus, ghrelin reduces serum HMGB1 levels and ameliorates gut barrier dysfunction in sepsis by vagus nerve activation via central ghrelin receptors. Ghrelin appears to be a novel agent to protect gut barrier function in sepsis.
